Chemosensitizers, especially those proven to be safe compounds, such as natural phenolic agents or their structural derivatives, could serve as potential “leads” against yeast pathogens for more effective treatment of mycoses using MRC inhibitory drugs. Here, CD200 is linked to opportunistic mycosis.